Scott L. Nyberg, M.D., Ph.D.
The research of Scott L. Nyberg, M.D., Ph.D., is focused on the development of a multidisciplinary bioartificial liver program to improve the treatment of patients with liver failure and support the Mayo Clinic clinical liver transplant program.
His lab is also involved with regenerative medicine of liver disease as it pertains to treating patients in liver failure with a bioartificial liver or treating patients with metabolic liver disease with hepatocyte transplantation.
The bioartificial liver is an important supportive therapy to bridge patients in liver failure to liver transplantation, or to avoid liver transplantation when spontaneous recovery is possible.
Similar to hemodialysis in the treatment of kidney failure, the bioartificial liver functions outside of the patient's body. However, the bioartificial liver is a "hybrid" extracorporeal device in that it contains hepatocytes, most commonly of porcine or human origin, as a biological source of liver function.
Dr. Nyberg's team has also developed its own liver support system, the Mayo Spheroid Reservoir Bioartificial Liver. This system functions using human hepatocytes produced in a novel genetically engineered animal, the HT1 pig, which serves as an in vivo incubator for robust expansion of human hepatocytes.
Additionally, Dr. Nyberg is director of the Mayo Clinic liver support program, a multidisciplinary team that participated in the pivotal evaluation of the HepatAssist bioartificial liver system.
Significance to patient care
Dr. Nyberg and his team expect that these studies will lead to a "humanized" bioartificial liver device for clinical treatment of patients with liver failure. Dr. Nyberg is also the leader of the Mayo Clinic Liver Regenerative Medicine Program.
Solid Organ Transplantation
Doctor of Philosophy
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.